Prospective Prediction of Viral Suppression and Immune Response Nine Months After ART Initiation in Seattle, WA

Overview

Journal AIDS Care

Publisher Informa Healthcare

Specialty Infectious Diseases

Date 2012 May 30

PMID 22639986

Citations 8

Authors

Jane M Simoni

Samantha S Yard

David Huh

Affiliations

Soon will be listed here.

Abstract

Knowing at antiretroviral therapy (ART) initiation which patients might be at greatest risk for failure to achieve viral suppression would enable providers to target patients most in need and tailor their care appropriately. This study involved multilevel modeling of data from a randomized controlled trial among outpatients in Seattle, WA, USA. The 224 participants initiating or switching ART at baseline were 24% female, 34% heterosexual, and 47% Caucasian. Of 24 baseline demographic and psychosocial patient-level variables modeled in separate generalized estimating equations, only employment predicted changes in HIV-1 RNA viral load or CD4 lymphocyte count over the course of the 9-month trial. Although the findings require replication, they suggest adherence support strategies should emphasize close monitoring and support for all patients initiating ART.

Citing Articles

Socioeconomic Status and CD4 Count Among People with HIV Who Inject Drugs in St. Petersburg, Russia.

Idrisov B, Van Draanen J, Lodi S, Lunze K, Kimmel S, Quinn E AIDS Behav. 2024; 28(7):2239-2246.

PMID: 38658481 PMC: 11537302. DOI: 10.1007/s10461-024-04316-z.

A Census Tract-Level Examination of HIV Care Outcomes and Social Vulnerability Among Black/African American, Hispanic/Latino, and White Adults in the Southern United States, 2018.

Elenwa F, Gant Z, Hu X, Satcher Johnson A J Community Health. 2023; 48(4):616-633.

PMID: 36823280 PMC: 9950007. DOI: 10.1007/s10900-023-01191-y.

Neighbourhood-level material deprivation and response to combination antiretroviral therapy in the Canadian Observational Cohort (CANOC): a longitudinal cohort study.

McClean A, Trigg J, Ye M, McLinden T, Kooij K, Bacani N CMAJ Open. 2022; 10(1):E183-E189.

PMID: 35292476 PMC: 8929426. DOI: 10.9778/cmajo.20200249.

Economic Burden Among Gay, Bisexual, and Other Men Who Have Sex With Men Living With HIV or Living Without HIV in the Multicenter AIDS Cohort Study.

Dean L, Nonyane B, Ugoji C, Visvanathan K, Jacobson L, Lau B J Acquir Immune Defic Syndr. 2020; 85(4):436-443.

PMID: 33136741 PMC: 7592888. DOI: 10.1097/QAI.0000000000002478.

Socioeconomic disparity of immunologic outcome among people living with HIV in Guangxi, China.

Yang X, Li X, Qiao S, Shen Z, Zhou Y AIDS Care. 2020; 33(3):347-351.

PMID: 32148069 PMC: 8232396. DOI: 10.1080/09540121.2020.1738004.

References

Kyser M, Buchacz K, Bush T, Conley L, Hammer J, Henry K . Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011; 23(5):601-11. DOI: 10.1080/09540121.2010.525603. View

Ortego C, Huedo-Medina T, Llorca J, Sevilla L, Santos P, Rodriguez E . Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011; 15(7):1381-96. DOI: 10.1007/s10461-011-9942-x. View

Simoni J, Amico K, Pearson C, Malow R . Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008; 10(6):515-21. PMC: 4059830. DOI: 10.1007/s11908-008-0083-y. View

Simoni J, Huh D, Frick P, Pearson C, Andrasik M, Dunbar P . Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009; 52(4):465-473. PMC: 2795576. DOI: 10.1097/qai.0b013e3181b9300c. View

Cescon A, Cooper C, Chan K, Palmer A, Klein M, Machouf N . Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. HIV Med. 2010; 12(6):352-60. DOI: 10.1111/j.1468-1293.2010.00890.x. View

Skinner H . The drug abuse screening test. Addict Behav. 1982; 7(4):363-71. DOI: 10.1016/0306-4603(82)90005-3. View

Lima V, Harrigan R, Bangsberg D, Hogg R, Gross R, Yip B . The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009; 50(5):529-36. PMC: 3606956. DOI: 10.1097/QAI.0b013e31819675e9. View

Yard S, Huh D, King K, Simoni J . Patient-level moderators of the efficacy of peer support and pager reminder interventions to promote antiretroviral adherence. AIDS Behav. 2011; 15(8):1596-604. PMC: 4044098. DOI: 10.1007/s10461-011-0001-4. View

Li X, Margolick J, Jamieson B, Rinaldo C, Phair J, Jacobson L . CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2011; 57(5):421-8. PMC: 3293185. DOI: 10.1097/QAI.0b013e31821e9f21. View

10.

Saunders J, Aasland O, Babor T, De la Fuente J, Grant M . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993; 88(6):791-804. DOI: 10.1111/j.1360-0443.1993.tb02093.x. View

11.

Fairbairn N, Kerr T, Milloy M, Zhang R, Montaner J, Wood E . Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Behav. 2011; 36(7):762-3. PMC: 3081981. DOI: 10.1016/j.addbeh.2011.02.001. View

12.

Cohen S, Kamarck T, Mermelstein R . A global measure of perceived stress. J Health Soc Behav. 1983; 24(4):385-96. View

13.

Holland J, Kash K, Passik S, Gronert M, SISON A, Lederberg M . A brief spiritual beliefs inventory for use in quality of life research in life-threatening illness. Psychooncology. 1999; 7(6):460-9. DOI: 10.1002/(SICI)1099-1611(199811/12)7:6<460::AID-PON328>3.0.CO;2-R. View

14.

Ammassari A, Trotta M, Murri R, Castelli F, Narciso P, Noto P . Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2003; 31 Suppl 3:S123-7. DOI: 10.1097/00126334-200212153-00007. View

15.

Carrico A, Bangsberg D, Weiser S, Chartier M, Dilworth S, Riley E . Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS. 2011; 25(8):1113-8. PMC: 3601574. DOI: 10.1097/QAD.0b013e3283463f09. View

16.

Lampe F, Smith C, Madge S, Kinloch-De Loes S, Tyrer M, Sabin C . Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med. 2007; 167(7):692-700. DOI: 10.1001/archinte.167.7.692. View

17.

Ironson G, OCleirigh C, Fletcher M, Laurenceau J, Balbin E, Klimas N . Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med. 2005; 67(6):1013-21. PMC: 2614887. DOI: 10.1097/01.psy.0000188569.58998.c8. View

18.

Simoni J, Amico K, Smith L, Nelson K . Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010; 7(1):44-51. PMC: 3607373. DOI: 10.1007/s11904-009-0037-5. View

19.

Sherbourne C, Stewart A . The MOS social support survey. Soc Sci Med. 1991; 32(6):705-14. DOI: 10.1016/0277-9536(91)90150-b. View

20.

Carballo E, Cadarso-Suarez C, Carrera I, Fraga J, de la Fuente J, Ocampo A . Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004; 13(3):587-99. DOI: 10.1023/B:QURE.0000021315.93360.8b. View